Abstract
In ARASENS (NCT02799602), darolutamide (DARO) + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death by 32.5% (HR 0.68, 95% CI 0.57–0.80; P<0.001) vs placebo (PBO) + ADT + docetaxel in patients (pts) with mHSPC. We investigated clinical outcomes in prespecified stratification subgroups based on extent of disease and alkaline phosphatase (ALP), both known prognostic factors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
